Full Press Release Details
ASX/Media Release (Code: ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034)
DISCUSS PRIMA BIOMED S CVAC CLINICAL TRIAL DATA IN OVARIAN
SYDNEY, AUSTRALIA - Prima BioMed Ltd (ASX: PRR; NASDAQ: PBMD; ISIN: US74154B2034) ( Prima , the Company ) announced that its recently
reported CVac clinical trial results will be the focus of an upcoming expert panel discussion entitled Ovarian Cancer: Next Generation Immunotherapies to be held via conference call on Thursday, December 12, 2013 at 8:00am Sydney
local time. This corresponds to Wednesday, December 11, at 4:00pm New York local time.
The moderated discussion will be sponsored by ProActive
Capital Group and features three medical experts in the fields of ovarian cancer and immunotherapy:
Heidi J. Gray, MD, Associate Professor, Department of
Obstetrics and Gynecology, University of Washington School of Medicine.
Jeffrey C. Goh, MBBS, of the Royal Brisbane and Women s Hospital in
Queensland, Australia.
Holbrook E. Kohrt, MD, PhD, Assistant Professor of Medicine (Oncology), Stanford University Medical Center; and Senior Clinical
Advisor to Prima BioMed Ltd.
The discussion will be moderated by Jason Kolbert, Senior Biotechnology Analyst at Maxim Group. A replay will be available
after the conclusion of the live event.
Conference call details:
| Australia | 1 800 838 758 | |
| Australia | 1 800 131 617 | |
| US/Canada | 1-855-237-2970 | |
| Germany | 0800 189 9369 |
Several immunotherapy approaches to management of ovarian cancer have entered the clinic in recent years, including Prima
BioMed s CVac. New treatment modalities are urgently needed in order to significantly improve the prognosis of women with epithelial ovarian cancer. The hope is that cancer immunotherapies may provide longer survival with lower toxicity than
associated with more traditional cancer treatments.
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284
According to the Cancer Research Institute, only modest progress has been made in improving overall survival in
patients with ovarian cancer over the past 20 years. Although the majority of women with advanced ovarian cancer respond to first-line chemotherapy, most responses are not durable. More than 70% of patients die of recurrent disease within 5 years of
The poor survival in advanced ovarian cancer is due both to late diagnosis, as well as to the lack of effective second-line therapy for
patients who relapse. The clinical course of ovarian cancer patients is marked by periods of remission and relapse of sequentially shortening duration until chemotherapy resistance develops.
Prima BioMed is a globally active biotechnology company. As a leader in personalized bio-therapeutic products for cancer, Prima is dedicated to leveraging its
current technology and expertise to develop innovative treatment options for patients and to maximize value to shareholders. Prima s lead product is CVac , an autologous dendritic cell product currently in clinical trials for ovarian
cancer patients who are in remission.
For further information please contact:
Ms. Jessica Brown, Prima BioMed
+1 (919) 710-9061; jessica.brown@primabiomed.com.au
Australia Investor/Media:
Mr. James Moses, Mandate
+61 (0) 420 991 574; james@mandatecorporate.com.au
Europe Investor/Media:
+49 (0) 69 905505-52; amuehlhaus@edicto.de
Prima BioMed Ltd, Level 7, 151 Macquarie Street, Sydney NSW 2000
Phone: +61 2 9276 1224 Fax: +61 2 9276 1284